Aytu Biopharma (AYTU) EBIT Margin (2013 - 2026)

Aytu Biopharma (AYTU) has 14 years of EBIT Margin data on file, last reported at 32.75% in Q1 2026.

• On a quarterly basis, EBIT Margin fell 4587.0% year-over-year to 32.75% in Q1 2026; TTM through Mar 2026 was 26.79%, a 2302.0% decrease from a year earlier, with the FY2025 full-year figure at 11.79%, down 935.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 32.75%, down from 12.99% in the prior quarter.
• Over the last five years, EBIT Margin for AYTU reached as high as 16.78% in Q4 2023 and fell as low as 220.76% in Q1 2022.
• Historically, EBIT Margin has averaged 28.07% across 5 years, with a median of 11.39% in 2024.
• Across the five-year window, EBIT Margin jumped 18311 bps in 2023 and plunged 4587 bps in 2026, its largest moves.
• Year by year, EBIT Margin stood at 26.13% in 2022, then jumped by 164 bps to 16.78% in 2023, then sank by 162 bps to 10.45% in 2024, then fell by 24 bps to 12.99% in 2025, then plunged by 152 bps to 32.75% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 32.75% in Q1 2026, 12.99% in Q4 2025, and 10.83% in Q3 2025.